Pharmacokinetics and pharmacodynamics of penbutolol in healthy and cancer subjects: Role of altered protein binding

Research Communications in Molecular Pathology and Pharmacology

Volumn 92, Issue 1, 1996, Pages 53-72

  Aguirre, Carmelo ^a   Trocóniz, Iñaki F ^a   Valdivieso, Andrés ^b   Jiménez, Rosa M ^a   Gonźalez, Jon P ^a   Calvo, Rosario ^a   Rodríguez Sasiaín, Jose M ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b HOSPITAL DE GALDAKAO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; OROSOMUCOID; PENBUTOLOL;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; HEART RATE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL;

ADULT; AGED; BINDING, COMPETITIVE; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PENBUTOLOL; PROTEIN BINDING;

EID: 0029988526     PISSN: 10780297     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Abramson, F. P. (1982). Methadone plasma protein binding: alterations in cancer and displacement from alpha1-acid glycoprotein. Clin. Pharmacol. Ther. 32: 652-658.
2. Aguirre, C., Calvo, R., and Rodríguez-Sasiaín , J.M. (1987). Características de la fijación plasmática de penbutolol en pacientes neoplásicos. Farm. Clin. 4: 264-374.
3. Aguirre, C., Rodríguez-Sasiaín, J.M., Navajas, P., and Calvo, R. (1988). Plasma protein binding of penbutolol in pregnancy. Eur. J. Drug Metabol. Pharmacokinet. 13: 23-26.
4. Akaike, H. (1974). A new look at the statistical model identification. IEEE Trans. Automat. Contr. 19: 716-723.
5. Beal, S.L., and Sheiner, L.B. (1989). NONMEM users guides. University of California, San Francisco.
6. Bernard, N., Cuisinaud, G., Pozet ,N., Zech, P.Y., and Sassard, J. (1982). Determination of penbutolol and its hydroxylated metabolite in biological fluids by reverse-phase high performance chromatography. J. Chromatogr. 228: 355-361.
7. Bernard, N., Cuisinaud, G., Pozet, N., Zech, P.Y., and Sassard, J. (1985). Pharmacokinetics of penbutolol and its metabolites in renal insufficiency. Eur. J. Clin. Pharmacol. 29: 215-219.
8. Branch, R.A., Jones, J., and Read, A.E. (1976). A study of factors influencing drug disposition in chronic liver disease, using the model drug (+)-propranolol. Br. J. Clin. Pharmacol. 3: 243-249.
9. Colangelo, P., Chandler, M., Bloutin, R., and McNamara, P. (1989). Stereoselective binding of propranolol in the elderly. Br. J. Clin. Pharmacol. 27: 519-522.
10. Dalton, W.S., Grogan, T.M, Meltzer, P.S., Scheper, R.J., Durie, B.G., Taylor, C.W., Miller, T.P., and Salmon, S.E. (1989). Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvection by addition of verapamil chemotherapy. J. Clin. Oncol. 7: 415-424.
11. Du Souich. P., Verges, J., and Erill, S. (1993). Plasma protein binding and pharmacological response. Clin. Pharmacokinet. 24: 435-440.
12. nd ed. Marcel Deker. New York.
13. Halliday, M.J., Dundee, J.W., Collier, P.S., Loughren, P.G., and Harper, K.W. (1985). Influence of plasma proteins on the onset of hypnotic action of intravenous midazolam. Anaesthesia 40: 763-766.
14. Inoue, M., Okajime, K., Itoh, K., Ando, Y., Watanabe, N., Yasaka, T., Nagase, S., and Morino, Y. Mechanism of furosemide resistance in analbuminemic rats and hypoalbuminemic patients. Kidney International 32: 198-203.
15. Jun, H.W., Hayes, S.L., Vallner, J.J., Honigberg, I.L., Rojos, A.E., and Stewart, J.T. (1979). Plasma levels profiles and clinical response of penbutolol after three different single oral doses in man. J. Clin. Pharmacol. 19: 415-423.
16. Kong, A., Ludwing, E.A., Slaughter, R.L., Diestefano, P.M., Demasi, J., Middleton, E., and Jusko, W.J. (1989). Pharmacokinetic and pharmacodynamic modeling of direct suppression effects of methylprednisolone on serum cortisol and blood histamine in human subjects. Clin. Pharmacol. Ther.46:616-628.
17. Koopmans, R., Ousterhuis, B., Karemaker, J.M., Wemer, J., and Van-Boxtel, C.J. (1988). Pharmacokinetic-pharmacodynamic modeling of oxprenolol in man using continuous non-invasive blood pressure monitoring. Eur. J. Clin. Pharmacol. 34: 395-400.
18. Lalonde, R.L., Straka, R.J., Pieper, J.A., Bortoff, M.B., and Mirvis, D.M. (1987). Propranolol pharmacodynamic modeling using unbound and total concentrations in healthy volunteers. J. Pharmacokin. Biopharm. 15: 569-582.
19. Lalonde, R.L., Tenero, D.M., Burlew, B.S., Herring, V.L., and Bottorff, M.B. (1990). Effects of age on the protein binding and disposition of propranolol stereoisomers. Clin. Pharmacol. Ther. 47: 447-55.
20. Martfnez-Jorda, R., Aguirre, C., Calvo, R., Rodríguez-Sasiaín, J.M., and Erill, S. (1990). Decrease in penbutolol response as a cause of changes in its serum protein binding. J. Pharm. Pharmacol. 42: 164-166.
21. 6-cyclopentyladenosine in the rat. J. Pharmacol. Exp. Ther. 268: 616-624.
22. Matsuki, Y., Katakuse, Y., Matsuura, H., Kiwada, H., and Goromatu, T. (1991). Effects of glucose and ascorbic acid on absorption and first pass metabolism of isoniazid in rats. Chem. Pharm. Bull. 39: 445-558.
23. McDevitt, DG., Frisk-Holmberg, M., Hollifield, J.W., and Shand, D.G. (1976). Plasma binding and the affinity of propranolol for a beta receptor in man. Clin. Pharmacol. Ther. 20: 152-157.
24. Meador, J., Sweet, P., Stupecky, M., Wetzel, M., Murray, S., Gupta, S., and Slater, L. (1987). Enhancement by cyclosporin A of daunorubicin efficacy in Ehrlich ascites carcinoma and murine hepatoma. Cancer Res. 47: 6216-6219.
25. Miner, D.J., Binkley, D.A., and Bechtol, L.D. (1984). Liquid Chromatographic determination of penbutolol and its principal metabolites in plasma and urine. Clin. Chem. 30: 717-723.
26. Paxton, J.W., and Briant, R.H. (1984). α1-acid glycoprotein concentrations and propranolol binding in elderly patients with acute illness. Br. J. Clin. Pharmac. 18: 806-810.
27. Piafsky, K.M. (1980). Disease-induced changes in the plasma binding of basic drugs. Clin. Pharmacokinet. 5: 246-262.
28. Piafsky, K.M., Borga, O., Odar-Cederlof, I., Johansson, C., and Sjoqvist, F. (1978). Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma α1-acid glycoprotein. N. Engl. J. Med. 299: 1435-1439.
29. Samuels, B.L., Mick, R., Vogelzang, N.J., Williams, S.F., Schilsky, R.L., Safa, A.R., O'Brien, S.M., and Ratain, M.J. (1993). Modulation of vinblastine resistance with cyclosporine: a phase I study. Clin. Pharmacol. Ther. 54: 421-429.
30. Schneider, R.E., and Bishop, H. (1982). β-blocker plasma concentrations and inflammatory disease: clinical implications. Clin. Pharmacokinet. 7: 281-284.
31. Schneider, R.E., Bishop, H., Kendall, M.J., and Quarterman, C.P. (1981). Effect of inflammatory disease on plasma concentrations of three β-adrenoreceptor blocking agents. Int. J. Clin. Pharmacol. Ther. Toxicol. 19: 158-162.
32. Shafer, S.L., Varvel, J.R., Aziz, N., and Scott, J.C. (1990). The pharmacokinetics of fentanyl administered by computer-controlled infusion pump. Anesthesiology 73:1091-1102.
33. Shoeman, D.W., and Azarnoff, D.L. (1975). Diphenylhydantoin potency and plasma protein binding. J. Pharmacol. Exp. Ther. 195: 84-86.
34. Slater, L., Sweet, P., Stupecky, M., Voelkel, E.F., Lloyd, W., Derynck, R., Winkler, M.E., and Levine, L. (1986). Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in-vitro. J. Clin. Invest. 77: 1405-1408.
35. Vallner, J.J., Jun, H.W., Needham, T.E., Stewart, J.T., Brown, W., Frazer, H., and Honigberg , I.L. (1977). Plasma levels studies of penbutolol after oral dose in man. J. Clin. Pharmacol. 4: 231-236.